PINELABS
Small CapPine Labs Limited
Pharma
Pine Labs is an Asia-focused commerce and fintech platform providing in-store & online infrastructure, affordability solutions, and issuing & acquiring services. It aims to build a global commerce OS, leveraging AI and expanding its network across merchants, brands, and financial institutions.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Weak fundamentals, management trust is acceptable, price trend argues for patience, and recent execution is mixed.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/3 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 31 Mar 2026
Average · 45/100Rev +17% YoY · margin expansion
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹701 Cr | +17.0% | -5.8% |
| EBITDA | ₹106 Cr | +86.0% | -19.7% |
| Operating margin | 15.0% | +600 bps | -300 bps |
| PAT | ₹59 Cr | NDF | +40.5% |
| PAT margin | 8.4% | +1326 bps | +277 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Where growth can come from, and what can break the case
Pine Labs reports strong Q4 FY26 and full-year FY26 results, with revenue up 17% YoY in Q4 and 19% YoY for FY26. Adjusted EBITDA surged 73% YoY in Q4 and 57% for FY26, achieving full-year PAT of ₹113 Cr, a significant swing from a loss.
The company demonstrated strong financial performance, achieving full-year profitability and significant EBITDA growth. Strategic focus on AI, international expansion, and key contract wins (OMCs) provide clear growth vectors. While Q4 saw some moderation due to seasonality and geopolitical factors, management's confidence in sustained growth and margin expansion supports the thesis.
Revenue by Geography
Latest issuer-disclosed distribution across 2 reported categories.
Online & Omnichannel Business
FY26 revenue grew 56% YoY, diversifying across categories with marquee enterprise merchants and new government, SMB & D2C mandates.
Affordability Platform
India's largest POS affordability network with 450+ brands and 40+ issuers; non-electronics volumes up 60%+ YoY (FY26).
Issuing & Acquiring Platform (IAP)
IAP segment grew 24% YoY in Q4, driven by distribution-led growth in India and expansion of embedded prepaid programs.
AI-Native Solutions & Agentic Commerce
Strategic partnerships with OpenAI and Google Gemini to co-create industry-first products and build AI-led solutions like SignalIQ.
Oil Marketing Companies (OMC) Contract Deployment
Won multi-year acquiring and loyalty mandates from Top 3 OMCs in India. Initial terminals went live in Q4 FY26, with ~130k terminals expected by end-FY27.
Network Effects
Emerging network effects across segments and platform, positioning Pine Labs as commerce infrastructure for the global south.
International Expansion
Exporting Indian fintech stack via RBI cross-border license and rolling out unified P2M platform across six geographies.
AI-Driven Efficiency & Innovation
AI is re-wiring the organization, optimizing operational processes, and creating new products like SignalIQ and Agentic Commerce Suite.
Geopolitical Situation
Heightened geopolitical situation in the Middle East mildly affected international business, impacting airline volumes and delaying product rollouts.
Seasonal Slowdown
Q4 FY26 growth moderated as it typically does after a strong festive season (Diwali), with brands and banks slowing consumption and spend-related budgets.
Hardware Cost Increase
Near-term rise in hardware costs amid the global chip shortage may moderate depreciation leverage going forward.
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
YoY comparison is crucial for assessing overall growth and profitability trends, especially given the seasonal nature of some business segments. QoQ comparison helps track sequential momentum and the impact of recent initiatives or short-term market dynamics.
Revenue from Operations
Q4 FY26: ₹701 Cr (+17% YoY); FY26: ₹2,711 Cr (+19% YoY).
Adjusted EBITDA
Q4 FY26: ₹146 Cr (+73% YoY); FY26: ₹559 Cr (+57% YoY).
Adjusted EBITDA Margin
Q4 FY26: 21% (+7% YoY); FY26: 21% (+5% YoY).
Profit After Tax (PAT)
Q4 FY26: ₹59 Cr (from -₹29 Cr YoY); FY26: ₹113 Cr (from -₹145 Cr YoY).
Sustained Revenue Growth
Management remains confident in sustaining revenue growth in the 21-23.5% range over the next few years, citing platform breadth and market wins.
Operating Leverage & Margin Expansion
Margin expansion is sustainable, driven by business mix change towards higher-margin revenue pools and operating leverage from existing infrastructure.
Owning the Commerce OS
Intent to move beyond payments processing to become the commerce infrastructure partner that merchants, financial institutions, and brands rely on to grow.
Investment in Future Growth
Continuing investments in people, technology, and geographies, with a focus on AI-based payments, deeper issuing & authentication, and credit at point of payment.
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Revenue Growth Rate | 19% YoY (FY26) | Sustaining growth within the 21-23.5% range over the next few years, as guided by management. |
| Adjusted EBITDA Margin | 21% (FY26) | Continued expansion of margins, driven by business mix enrichment and operating leverage, as stated by management. |
| OMC Terminal Deployment | Initial terminals live (Q4 FY26) | Ramp-up to ~130,000 consolidated fuel-retail POS terminals by end-FY27, as per contract timelines. |
| International Revenue Contribution | 15% of total revenue (FY26) | Continued growth in international revenue share, reflecting successful execution of phased market-entry strategy. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Show extracted source claims
Pine Labs aims to build a global commerce and fintech platform originating from Asia.
Pine Labs plans to extend its programmable currency platform to a wider range of use cases and industries beyond airlines.
Pine Labs is planning to launch a go-to-market strategy for its patented Tap to Pay Online technology both in India and globally.
Trend score and candlestick chart
44NeutralSMA20 -25.6% / mo · near 52W low
Technical chart
PINELABSdaily · 6M-37.1%Technical trend read
Mixed signalsSignals are conflicting — long-term trend unclear. RSI 46. Wait for confirmation.
- SMA20 falling (~32.7% over last month) — short-term momentum negative.
- RSI(14) at 46 — rising, no extreme reading.
- MACD above signal, histogram expanding — bullish momentum building.
- 39% off 52W high · 13% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation, score drivers, trust methodology, financials, and peers
Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.
Fundamental score breakdown
WATCHLISTWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Piotroski is strong at 8/9.
- Growth contributes 15/25 to the score.
- Balance sheet contributes 8/15 to the score.
Main drags
- Fair-value margin of safety is negative at -270.2%.
- Quality is weaker at 0/20; verify the latest quarterly trend.
- Valuation is weaker at 2/30; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: +0 points.
Factor attribution
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Mixed Trust: Claim history is still being built. It ranks around the 27th percentile of the scored universe and 20th percentile within Pharma. Main check: cash conversion is weak at 43/100.
Healthy Trust Lite: Promoter pledge is zero. Key concern: Only 1 years of positive FCF.
Usable, but needs evidence. Treat guidance with a margin of safety.
overall median 67 · Pharma: 20th pctile, median 70 · Small: 31st pctile, median 65
22 documents indexed, but claim history is not strong enough yet.
3 claims extracted · No contradicted claim yet
How to read this Trust Score
Mixed Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter pledge is zero.
- ▸Debt/equity is 0.07.
Trust risks
- ▸Only 1 years of positive FCF.
- ▸ROCE is low at 4.2%.
- ▸ROE is low at 2.5%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Intrinsic value
Fundamentals
Valuation
- P/E
- 143.00
- P/B
- 2.79
- EV/EBITDA
- 26.82
- Market Cap
- 16400.00Cr
Profitability
- ROE
- 2.46%
- ROCE
- 4.16%
- ROA
- 0.85%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 32.00%
- EPS 5Y
- 32.00%
- Revenue 3Y
- 19.00%
- EPS 3Y
- 36.00%
Balance Sheet
- Debt/Equity
- 0.07
- Interest Coverage
- 4.26×
- Altman Z
- 2.39
- Book Value
- 51.30
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 1/5
- OCF
- 395.00 Cr
- EPS TTM
- 0.98
Shareholding
- Promoter Hold
- —
- Promoter Pledge
- 0.00%
- Momentum 52W
- 5%
Financial History
Updated 9/6/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.